Orphazyme20.jpg

INVESTORS & MEDIA

INVESTORS & MEDIA

Orphazyme is a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative rare diseases.

We are committed to providing relevant, accurate and timely information to investors and the financial community. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH).

 

Latest Announcements

Share Price

Read more

Upcoming Events

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site.

Sign up here

IR Contact

anders

Anders Vadsholt

CFOTel: (+45) 28 98 90 55E-mail: afv@orphazyme.com